Blood Cells, Molecules and Diseases

Journal

Publication Venue For

  • Metabolic syndrome among adults living with sickle cell disease.  74:25-29. 2019
  • White blood cells and subtypes in HFE p.C282Y and wild-type homozygotes in the Hemochromatosis and Iron Overload Screening Study.  63:9-14. 2017
  • New insights provided by a comparison of impaired deformability with erythrocyte oxidative stress for sickle cell disease.  52:230-235. 2014
  • Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 Hemochromatosis and Iron Overload Screening (HEIRS) Study participants.  44:252-256. 2010
  • Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.  43:119-128. 2009
  • Post-translational modifications of Runx1 regulate its activity in the cell.  43:30-34. 2009
  • A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.  42:155-158. 2009
  • Heme carrier protein 1 (HCP1) genetic variants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study participants.  42:150-154. 2009
  • Heme degradation and oxidative stress in murine models for hemoglobinopathies: Thalassemia, sickle cell disease and hemoglobin C disease.  41:60-66. 2008
  • SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent.  39:206-211. 2007
  • Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.  38:247-252. 2007
  • Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.  37:100-106. 2006
  • Three kinships with ALAS2 P520L (c. 1559 C → T) mutation, two in association with severe iron overload, and one with sideroblastic anemia and severe iron overload.  36:292-297. 2006
  • HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: Frequency disparity in men and women and lack of association with severity of iron overload.  34:38-47. 2005
  • Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: A role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation.  32:182-190. 2004
  • Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y.  31:102-111. 2003
  • Genotypic and phenotypic heterogeneity of African Americans with primary iron overload.  31:310-319. 2003
  • Intranuclear organization of RUNX transcriptional regulatory machinery in biological control of skeletogenesis and cancer.  30:170-176. 2003
  • Late effects among survivors of leukemia during childhood and adolescence.  31:84-92. 2003
  • The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.  30:201-206. 2003
  • Juvenile hemochromatosis in the southeastern United States: A report of seven cases in two kinships.  29:104-115. 2002
  • Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.  27:610-624. 2001
  • Transferrin receptor-2 (TFR2) mutation Y250X in Alabama Caucasian and African American subjects with and without primary iron overload.  27:279-284. 2001
  • Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands.  25:147-155. 1999
  • Genetic and clinical description of hemochromatosis probands and heterozygotes: Evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis.  23:135-145. 1997
  • Hemochromatosis: Association of severity of iron overload with genetic markers.  22:195-204. 1996
  • International Standard Serial Number (issn)

  • 1079-9796
  • Electronic International Standard Serial Number (eissn)

  • 1096-0961